Genmab A (GMAB) Enterprise Value: 2018-2021
- Genmab A's Enterprise Value rose 22.30% to $26.5 billion in Q2 2021 from the same period last year, while for Jun 2021 it was $27.0 billion, marking a year-over-year increase of 21.76%. This contributed to the annual value of $13.8 billion for FY2024, which is 34.35% down from last year.
- According to the latest figures from Q2 2021, Genmab A's Enterprise Value is $26.5 billion, which was down 2.00% from $27.1 billion recorded in Q4 2020.
- Over the past 5 years, Genmab A's Enterprise Value peaked at $27.1 billion during Q4 2020, and registered a low of $10.9 billion during Q4 2018.
- Its 3-year average for Enterprise Value is $20.3 billion, with a median of $21.7 billion in 2020.
- Data for Genmab A's Enterprise Value shows a peak YoY soared of 85.40% (in 2020) over the last 5 years.
- Quarterly analysis of 4 years shows Genmab A's Enterprise Value stood at $10.9 billion in 2018, then skyrocketed by 34.48% to $14.6 billion in 2019, then surged by 85.40% to $27.1 billion in 2020, then rose by 22.30% to $26.5 billion in 2021.
- Its last three reported values are $26.5 billion in Q2 2021, $27.1 billion for Q4 2020, and $21.7 billion during Q2 2020.
